Name: Zhou,Xiaoyan
Title:Professor, pathologist, Ph.D supervisor, executive vice director of Cancer Research Laboratory.

Education & Professional Experience   She received her Bachelor's degree in medicine in 1988 and Master degree in pathology in 1991 from Nantong Medical College and earned her Ph.D degree in oncology in 1998 from Shanghai Medical University (now merged into Fudan University). She has further studied as a post-doctoral fellow in The Department of Surgical Oncology between 2002 and 2004 in M.D. Anderson Cancer Center, USA.
Specialty   Molecular diagnosis in clinical practice
Research   Her major research area is of investigating molecular mechanisms of malignancies, especially in lymphoma and colorectal cancer.
Publication   1.Yu B, Zhou X,.Li B, Xiao X, Yan S, Shi D. FOXP1 Expression and its clinicopathologic significance in nodal and extranodal Diffuse large B-cell lymphoma. Ann Hematol 2010 (Accepted)
2.Zhu X, Lu Y, Lu H, Yang W, Tu X, Cai X, Zhou X.. A Study on the Association of HER2 Gene Status and Protein Expression and the impact of Chromosome 17 Polysomy on HER2 Determination in Breast Cancer. Human Pathology 2010 (Accepted)
3.Huang W , Li X, Yao X, Lu Y, Li B, Sheng W, Lu H, Jin A, Zhou X . Expression of ALK protein mRNA and fusion transcripts in anaplastic large Cell lymphoma. Exp Mol Pathol 2009,86: 121-126
4.YU B, Zhou X, Zhang T, Shi D. A study on Mutation of PIK3CA Gene in Diffuse Large B Cell Lymphoma. Diag Mol Pathol, 2008;17(30 159-165
5.Chao-fu WANG, Xiao-yan ZHOU , Tai-ming ZHANG, Ye XU, San-jun CAI, Da-ren SHI. Two Novel Germline Mutations of MLH1 and Investigation of their pathobiology in Hereditary Non-Polyposis Colorectal Families from China. World J Gastroenterol. 2007;13(46):6254-6258
6.Wang CF, Zhou XY, Zhang TM, Sun MH, Shi DR. Detection of germline mutation of hMLH1 and hMSH2 based on cDNA sequencing in China. World J Gastroenterol 2005; 11(42):6620-6623
7.Zhou X., Tan M., Stone V., Lan K.H., Yang Y., Yang W., Smith T.L., Shi D., Yu D. Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Caner Res 2004;10:6779-6788
8.Min D, Zhou X, Yang W, Lu H, Zhang T, Zhen A, Cao P, Shi D.Point mutation of the 5’noncoding region of the bcl-6 gene in primary gastric lymphomas. World J Gastroenterol 2005;11(1):51-5
9.Xiao X, Zhou X, Yan G, Sun M, Du X. Studies of Genomic Alteration in Sporadic Colorectal Carcinomas by comparative genomic hybridization and its significance. Diag Mol Pathol 2007;16(2):96-103
10.Nagata, Y*.,and Lan, K.H*., Zhou, X., Esteva, F.J., Sahin, A.A., Klos, K.S., Monia B.P, Nguyen, N.T., Hortobagyi, G.N. Hung M.C.and Yu, D. PTEN activation contributes to tumor inhibition by Trastuzumab and loss of PTEN predicts Trastuzumab resistance in breast cancer patients. Cancer Cell. 2004 Aug;6(2):117-27
11.Sellappan S* ,and Grijalva, R*., Zhou, X., Yang, W.,.Bareli M., Mills G.B., Yu, D. Lineage infidelity of MDA-MB-435 cells: Expression of melanocyte proteins in a breast cell line. Cancer Res, 2004,64(10):3479-85
12.Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004 Nov;6(5):459-69.
13.Klos, K.S., Zhou, X., Lee S.K., Zhang L., Yang, W., Nagata Y., Yu, D. Combined Trastuzumab and paclitaxel Treatment better inhibits ErbB-2-Mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer . 2003;98(7):1377-85
14.Yang, W., Klos, K.S., Zhou, X., Yao, J., Yang, Y., Smith, T.L. Shi, D. and Yu, D. ErbB2 overexpression in human breast cancer correlates with p21Cip1 upregulation, tyrosine-15 hyperphosphorylation of p34Cdc2 , and poor responsiveness to CMF in patients with ErbB2 and p21cip overexpression. Cancer 2003 ;98(6):1123-30
Awards   4 research awards by the National Natural Science Foundation of China (NSFC) and 5 research awards by the University and Science and Technology Commission of Shanghai Municipality
Out-patient Schedule